1. Home
  2. IGI vs KPTI Comparison

IGI vs KPTI Comparison

Compare IGI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGI
  • KPTI
  • Stock Information
  • Founded
  • IGI 2009
  • KPTI 2008
  • Country
  • IGI United States
  • KPTI United States
  • Employees
  • IGI N/A
  • KPTI N/A
  • Industry
  • IGI Investment Managers
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • IGI Finance
  • KPTI Health Care
  • Exchange
  • IGI Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • IGI 102.0M
  • KPTI 102.4M
  • IPO Year
  • IGI N/A
  • KPTI 2013
  • Fundamental
  • Price
  • IGI $16.51
  • KPTI $5.59
  • Analyst Decision
  • IGI
  • KPTI Strong Buy
  • Analyst Count
  • IGI 0
  • KPTI 7
  • Target Price
  • IGI N/A
  • KPTI $29.71
  • AVG Volume (30 Days)
  • IGI 33.9K
  • KPTI 328.0K
  • Earning Date
  • IGI 01-01-0001
  • KPTI 11-03-2025
  • Dividend Yield
  • IGI 4.79%
  • KPTI N/A
  • EPS Growth
  • IGI N/A
  • KPTI N/A
  • EPS
  • IGI N/A
  • KPTI N/A
  • Revenue
  • IGI N/A
  • KPTI $142,530,000.00
  • Revenue This Year
  • IGI N/A
  • KPTI $4.87
  • Revenue Next Year
  • IGI N/A
  • KPTI $9.20
  • P/E Ratio
  • IGI N/A
  • KPTI N/A
  • Revenue Growth
  • IGI N/A
  • KPTI N/A
  • 52 Week Low
  • IGI $15.13
  • KPTI $3.51
  • 52 Week High
  • IGI $17.79
  • KPTI $14.24
  • Technical
  • Relative Strength Index (RSI)
  • IGI 37.67
  • KPTI 41.51
  • Support Level
  • IGI $15.78
  • KPTI $5.46
  • Resistance Level
  • IGI $16.87
  • KPTI $6.17
  • Average True Range (ATR)
  • IGI 0.20
  • KPTI 0.43
  • MACD
  • IGI -0.03
  • KPTI -0.06
  • Stochastic Oscillator
  • IGI 63.48
  • KPTI 10.08

About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.

Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: